€7.5 million fresh capital to advance first-in-human studies and accelerate market entry
We are very pleased to announce that we have reached another milestone in the establishment of our Therapy Assistance CT, securing €5 million in venture capital and €2.5 million in EIC Accelerator funding.
Dr. Thomas Hoffmann, CEO and co-founder of RAYDIAX: “With the successful closing of our Series A1, we have reached a decisive milestone on our path toward clinical application. Following the successful seed phase and the development of our preclinical prototype, we are now focusing on generating early clinical evidence as part of the planned first-in-human studies. At the same time, we are establishing the organizational foundations for market entry. The continued trust of our existing investors, along with the support of new strategic partners, confirms the technological maturity and market potential of our approach.”
Ready for Innovation?
We know that the methods of minimally invasive therapies continue to offer great potential for clinical innovation. Would you also like to establish your operating technique? Make a suggestion, define a joint project and research your case on our system in phantom studies. And of course we are open to clinical publications.
